<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04376892</url>
  </required_header>
  <id_info>
    <org_study_id>IKCU2</org_study_id>
    <nct_id>NCT04376892</nct_id>
  </id_info>
  <brief_title>Quality of Life and Exercise Capacity in COPD</brief_title>
  <official_title>The Effect of Exercise Capacity on Quality of Life in COPD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Izmir Katip Celebi University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Izmir Katip Celebi University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      COPD patients will be examined in 4 groups according to their walking distance. Patients
      walking under 150 meters will be determined as Group 1, those walking between 150-249 meters
      will be Group 2, those walking between 250-349 meters will be selected as Group 3, and
      patients with COPD who walk 350 and above will be determined as Group 4. The groups were
      compared in terms of quality of life, psychological symptoms and dyspnea.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Quality of life affects the mortality rate independently in patients with COPD. The treatment
      applied in COPD does not stop the decrease in lung function, nor does it prolong the survival
      time. Spirometric evaluations to determine the severity of the disease are not sufficient to
      explain the perception of patients and their adaptation to their diseases. Therefore,
      evaluating the quality of life has become an important measure of treatment in COPD patients.
      Quality of life measurements should be done to minimize the effect of the disease, to help
      patients better cope with the consequences of an incurable long-term condition, and to
      determine modifiable factors. Identifying modifiable factors; in personalized treatment
      adopted in airway diseases in recent years; it is important to be able to apply appropriate
      pharmacological and non-pharmacological treatments Our aim is to exercise capacity in COPD
      patients; firstly to investigate the effect on quality of life, then to determine the
      relationship between emergency admission and hospitalization, dyspnea, psychological
      symptoms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2013</start_date>
  <completion_date type="Actual">May 2020</completion_date>
  <primary_completion_date type="Actual">September 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life questionnaire</measure>
    <time_frame>20 minutes</time_frame>
    <description>St. George Respiratory Questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dyspnea Severity</measure>
    <time_frame>5 minutes</time_frame>
    <description>mMRC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Function</measure>
    <time_frame>20 minutes</time_frame>
    <description>Respiratory Function Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety Depression</measure>
    <time_frame>20 minutes</time_frame>
    <description>Hospital anxiety and Depression Qustionnaire</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">516</enrollment>
  <condition>Copd</condition>
  <condition>Quality of Life</condition>
  <condition>Exercise Capacity</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Exercise capacity under 149 meter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Exercise capacity between 150 and 249 meter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <description>Exercise capacity between 250 and 349 meter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <description>Exercise capacity above 340</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality of life measurement</intervention_name>
    <description>Quality of life measurement by St. George Respiratory questionnaire</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        COPD patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COPD patients completed all tests and qustionnaires

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Above 18</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 4, 2020</study_first_submitted>
  <study_first_submitted_qc>May 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2020</study_first_posted>
  <last_update_submitted>May 4, 2020</last_update_submitted>
  <last_update_submitted_qc>May 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Izmir Katip Celebi University</investigator_affiliation>
    <investigator_full_name>Ilknur Naz</investigator_full_name>
    <investigator_title>Assoc. Prof.</investigator_title>
  </responsible_party>
  <keyword>copd</keyword>
  <keyword>quality of life</keyword>
  <keyword>exercise capacity</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

